icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 22-25, 2016, Boston MA
Back grey_arrow_rt.gif
 
 
 
Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis
 
 
  Reported by jules Levin
CROI 2016 Feb 22-24 Boston
 
Jay A. Grobler, Ming-Tain Lai, Stephanie E. Barrett, Marian Gindy, Kerry Fillgrove, Wendy Ankrom, Sandra Wood, Evan Friedman, Marian Iwamoto, Daria J. Hazuda on behalf of the MK-8591 Early Development Team (West Point, PA)
Merck & Co., Inc. Kenilworth, NJ, USA
 
WEBCAST link: http://www.croiwebcasts.org/console/player/29624?mediaType=audio&
 

APASL1

APASL2

APASL3

APASL4

APASL5

APASL6

APASL7